PICO Portalanswers from OpenAlex & ORCID
P. Kelly Marcom
ResearcherPublications, citations & collaboration network
P. Kelly Marcom is a researcher indexed in PICO Portal from OpenAlex & ORCID.
How many works does P. Kelly Marcom have?
PICO Portalindexed works
P. Kelly Marcom has 191 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does P. Kelly Marcom have?
PICO Portalcitation count
P. Kelly Marcom has 18,397 citations in the OpenAlex counts PICO Portal stores.
What is the h-index of P. Kelly Marcom?
PICO Portalh-index
P. Kelly Marcom has an h-index of 57 in OpenAlex.
What is the i10-index of P. Kelly Marcom?
PICO Portali10-index
P. Kelly Marcom has an i10-index of 99 in OpenAlex.
What is the ORCID of P. Kelly Marcom?
PICO Portalorcid
The ORCID for P. Kelly Marcom is on the source record.
What is the OpenAlex record for P. Kelly Marcom?
PICO Portalopenalex
The OpenAlex for P. Kelly Marcom is on the source record.
What are the most-cited papers on P. Kelly Marcom?
PICO Portalmost cited works
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
William J. Gradishar, Benjamin O. Anderson, Jame Abraham, Rebecca Aft, Doreen M. Agnese, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau T. Dang, Anthony Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Jairam Krishnamurthy, Janice A. Lyons, P. Kelly Marcom, Jennifer M. Matro, Ingrid A. Mayer, Meena S. Moran, Joanne Mortimer, Ruth O’Regan, Sameer A. Patel, Lori J. Pierce, Hope S. Rugo, Amy M. Sitapati, Karen L. Smith, Mary Lou Smith, Hatem Soliman, Erica Stringer-Reasor, Melinda L. Telli, John H. Ward, Jessica Young, Jennifer L. Burns, Rashmi Kumar
Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer
Kathy D. Miller, Linnea Chap, Frankie A. Holmes, Melody Cobleigh, P. Kelly Marcom, Louis Fehrenbacher, Maura N. Dickler, Beth Overmoyer, James D. Reimann, Amy P. Sing, Virginia K. Langmuir, Hope S. Rugo
Whole-genome analysis informs breast cancer response to aromatase inhibition
Matthew J. Ellis, Li Ding, Dong Shen, Jingqin Luo, Vera J. Suman, John W. Wallis, Brian Andrew Van Tine, Jeremy Hoog, Reece Goiffon, Theodore C. Goldstein, Sam Ng, Lin Li, Robert J. Crowder, Jacqueline Snider, Karla V. Ballman, Jason D. Weber, Ken Chen, Daniel C. Koboldt, Cyriac Kandoth, William Schierding, Joshua F. McMichael, Christopher A. Miller, Charles Lu, Christopher Harris, Michael D. McLellan, Michael C. Wendl, Katherine DeSchryver, D. Craig Allred, Laura J. Esserman, Gary Unzeitig, Julie A. Margenthaler, Gildy V. Babiera, P. Kelly Marcom, J. Michael Guenther, Marilyn Leitch, Kelly K. Hunt, John A. Olson, Tao Yu, Christopher A. Maher, Lucinda Fulton, Robert S. Fulton, Michelle Harrison, Ben Oberkfell, Feiyu Du, Ryan Demeter, Tammi L. Vickery, Adnan Elhammali, Helen Piwnica‐Worms, Sandra McDonald, Mark A. Watson, David J. Dooling, David M. Ota, Li-Wei Chang, Ron Bose, Timothy J. Ley, David Piwnica‐Worms, Joshua M. Stuart, Richard K. Wilson, Elaine R. Mardis
Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
Sara M. Tolaney, William T. Barry, Chau T. Dang, Denise A. Yardley, Beverly Moy, P. Kelly Marcom, Kathy S. Albain, Hope S. Rugo, Matthew J. Ellis, Iuliana Shapira, Antonio C. Wolff, Lisa A. Carey, Beth Overmoyer, Ann H. Partridge, Hao Guo, Clifford A. Hudis, Ian E. Krop, Harold J. Burstein, Eric P. Winer
Genetic/Familial High-Risk Assessment: Breast and Ovarian
Mary B. Daly, Jennifer E. Axilbund, Saundra S. Buys, Beth Crawford, Carolyn Farrell, Susan Friedman, Judy E. Garber, Salil Goorha, Stephen B. Gruber, Heather Hampel, Virginia Kaklamani, Wendy Kohlmann, Allison W. Kurian, Jennifer K. Litton, P. Kelly Marcom, Robert L. Nussbaum, Kenneth Offit, Tuya Pal, Boris Pasche, Robert Pilarski, Gwen Reiser, Kristen M. Shannon, Jeffrey R. Smith, Elizabeth M. Swisher, Jeffrey N. Weitzel